AGC Biologics and RoosterBio have launched a strategic partnership to create an end-to-end solution for the development and production of hMSC and exosome therapeutics.
Biomanufacturing company National Resilience has announced a strategic collaboration with Mayo Clinic in biomanufacturing to deliver novel biotherapeutics for rare and complex conditions.
Charles River Laboratories, International Inc. has received regulatory approval - in the form of Good Manufacturing Practice (GMP) certification - to commercially produce allogeneic cell therapy drug products for distribution in Europe, from the European...
Millipore Sigma has launched its VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform: meaning the CDMO can now provide a full viral vector manufacturing offering including AAV, Lentiviral, CDMO, CTO, and process development.
Pfizer is planning to deliver COVID-19 vaccines against two sets of omicron subvariants in the autumn in the belief its “robust manufacturing capabilities” are up to the task.
Edinburgh CDMO RoslinCT and Massachusetts CDMO Lykan Bioscience will combine to create a global advanced therapies CDMO: offering significantly expanded manufacturing capacity.
A $76m investment in the facility in Grand Island, New York, will increase capacity to produce raw materials used in manufacture of vaccines and biologic therapies.
GreenLight Biosciences and Samsung Biologics have completed the first commercial-scale engineering run under the companies’ mRNA production partnership: ahead of a COVID-19 vaccine booster clinical trial due to start later this year.
Construction of Samsung Biologics’ Plant 4 is on schedule with operations set to start in October, the company confirmed in its Q2 results this morning.
CDMO WuXi Biologics will invest $1.4bn in a 10 year investment plan to expand its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.
SK bioscience has extended its partnership with Novavax to include the manufacture and supply of Novavax’s Omicron COVID-19 vaccine candidate, which could become available later this year.
Wacker Biotech’s site in Halle, Germany will be expanded in the coming months into a competence center for actives based on messenger ribonucleic acid (mRNA).
Fujifilm Corporation is to invest US$1.6bn (€1.4bn) to boost the business of its subsidiary, Fujifilm Diosynth Biotechnologies (FDB), a contract development and manufacturing organization (CDMO).
Construction works on an mRNA manufacturing facility have started in Kigali, Rwanda: as BioNTech works to create a pan-African end-to-end manufacturing network for mRNA-based vaccines.
VIVEbiotech has completed the latest expansion phase of its lentiviral vector manufacturing capabilities; the development is aimed at alleviating the viral vector bottleneck for advanced therapies.
Umoja Biopharma and TreeFrog Therapeutics have formed an alliance to address challenges facing ex vivo allogeneic therapies in immuno-oncology, including issues scaling up production to reach all patients.
Charles River Laboratories International and ASC Therapeutics have announced plans to manufacture ASC618, a second-generation gene therapy for hemophilia A.
Evonik will build a production facility for pharmaceutical lipids in Indiana: with the new site ‘positioning the group for future growth in novel mRNA-based therapies beyond COVID-19 vaccines’.
The agreement, which was made in coordination between the US army and BARDA, will see Jubilant expand its injectable filling production capacity to prepare for future pandemics.
Eli Lilly and Company plans to expand its manufacturing footprint in Indiana by investing $2.1bn in two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County.
AGC Biologics will add viral vector suspension technology and capacity for the development and manufacturing of gene therapies at its commercial-grade campus in Longmont, Colorado.
Inventprise has inaugurated its new manufacturing facility for high-capacity supply of a 25-valent Pneumococcal Conjugate Vaccine (IVT-PCV-25) for low- and middle-income countries.
Cytiva is opening a new 7,400m² manufacturing facility in Grens, Switzerland this month: which will serve as a center of excellence for the company’s cell and gene therapy business as well as a being a base for European customer training programs.
CDMO Matica Bio has opened a new 45,000-square-foot facility dedicated to the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other genetic medicines.
An expert from Pharmatech Associates offers a glimpse into the evolution of CM and previews a lively discussion during the upcoming CPhI North America event.
The US will play a key role in the development of advanced manufacturing technologies, predicts a report commissioned by CPhI North America ahead of the 2022 show.
Catalent has announced a multi-year $350m investment at its facility in Bloomington, Indiana, to expand biologics drug substance and drug product manufacturing capabilities.
Quay Pharma, a contract development and manufacturing organization (CDMO), has signed a contract with drug development specialist, Liveome, in relation to the Korean firm’s live biotherapeutic program.
Germany has made a series of contracts with vaccine manufacturers to reserve mRNA manufacturing capacity in the country as part of its pandemic preparedness plans.
US company Catalent is acquiring the UK’s Vaccine Manufacturing and Innovation Centre in Harwell: a facility which had been planned to support COVID-19 and wider vaccine production and which is still under construction.
The US Food and Drug Administration (FDA) has granted commercial licensure approval for Novartis’ Durham, N.C. site, a multi-product gene therapy manufacturing facility, which will start producing Zolgensma immediately.
eTheRNA Manufacturing, a specialist RNA process developer and manufacturing member of the eTheRNA group, has introduced a new lipid nanoparticle (LNP) formulation, development and production service.
CytoImmune Therapeutics, a clinical-stage immunotherapy company developing a novel class of engineered natural killer (NK) cell-based cancer therapies, has announced the opening of its clinical cell manufacturing facility in Toa Baja, Puerto Rico.
The Cell and Gene Therapy Catapult (CGT Catapult) has today published the ‘National Cell and Gene Therapy Vision for the UK’, a document outlining recommendations for a national strategy for the adoption of cell and gene therapies.
Moderna has finalized a strategic partnership with the Australian government to build an mRNA manufacturing facility in Melbourne: which is expected to produce up to 100 million mRNA respiratory vaccine doses annually.
A California based biotech has tripled its capacity to manufacture GMP grade induced pluripotent stem cells (iPSC) space through the expansion of its contract development and manufacturing (CDMO) facility.
Nutcracker Therapeutics, a biotech developing RNA therapeutics using its proprietary biochip-based manufacturing platform, has raised $167m in Series C financing: allowing it to expand and advance its pipeline of mRNA medicines for cancer and further...
